American Association for Cancer Research
10780432ccr190101-sup-215156_4_supp_5669040_pv6y6j.doc (39.5 kB)

Table S2 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Download (39.5 kB)
journal contribution
posted on 2023-03-31, 21:11 authored by Zi-Xun Yan, Li Li, Wen Wang, Bin-Shen OuYang, Shu Cheng, Li Wang, Wen Wu, Peng-Peng Xu, Muharrem Muftuoglu, Ming Hao, Su Yang, Mu-Chen Zhang, Zhong Zheng, James Li, Wei-Li Zhao

Supplementary Table S2: Amount and potency of CAR T cells


National Natural Science Foundation of China

Chang Jiang Scholars Program, Shanghai Commission of Science and Technology

Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant



Anti-CD19 chimeric antigen receptor (CAR) T cells represent a novel immunotherapy and are highly effective in treating relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). How tumor microenvironment influences clinical response to CAR T therapy remains of great interest. A phase I, first-in-human, dose-escalation study of anti-CD19 JWCAR029 was conducted in refractory B-NHL (NCT03355859) and 10 patients received CAR T cells at an escalating dose of 2.5 × 107(n = 3), 5 × 107(n = 4), and 1 × 108(n = 3) cells. Core needle biopsy was performed on tumor samples collected from diffuse large B-cell lymphoma patients on Day −6 (1 day before lymphodepletion) and on Day 11 after CAR T-cell infusion when adequate CAR T-cell expansion was detected. The overall response rate was 100%, with 6 of 9 (66.7%) evaluable patients achieving complete remission. The most common adverse events of grade 3 or higher were neutropenia (10/10, 100%), anemia (3/10, 30%), thrombocytopenia (3/10, 30%), and hypofibrinogenemia (2/10, 20%). Grade 1 cytokine release syndrome occurred in all patients and grade 3 neurotoxicity in 1 patient. The average peak levels of peripheral blood CAR T cells and cytokines were similar in 3 different dose levels, but CAR T cells were significantly higher in patients achieved complete remission on Day 29. Meanwhile, RNA sequencing identified gene expression signatures differentially enriched in complete and partial remission patients. Increased tumor-associated macrophage infiltration was negatively associated with remission status. JWCAR029 was effective and safe in treating refractory B-NHL. The composition of the tumor microenvironment has a potential impact in CAR T therapy response.

Usage metrics

    Clinical Cancer Research



    Ref. manager